Company Description
Recursion Pharmaceuticals, Inc. operates as a clinical-stage biotechnology company, engages in the decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery.
The company develops REC-994, which is in Phase IIa clinical trial to treat cerebral cavernous malformation; REC-2282 for the treatment of neurofibromatosis type 2; REC-4881 to treat familial adenomatous polyposis; and REC-3599, which is in Phase I clinical trial to treat GM2 gangliosidosis.
Its preclinical stage product includes REC-3964 to treat Clostridium difficile colitis; REC-64917 for the treat of neural or systemic inflammation; REC-65029 to treat HRD-negative ovarian cancer; REC-648918 to enhance anti-tumor immune; REC-2029 for the treatment of wnt-mutant hepatocellular carcinoma; REC-14221 to treat solid and hematological malignancies; and REC-64151 for the treatment of immune checkpoint resistance in KRAS/STK11 mutant non-small cell lung cancer.
The company has collaboration and agreement with Bayer AG; the University of Utah Research Foundation; Ohio State Innovation Foundation; Chromaderm, Inc.; and Takeda Pharmaceutical Company Limited.
Recursion Pharmaceuticals, Inc. was incorporated in 2013 and is headquartered in Salt Lake City, Utah.
| Country | United States |
| IPO Date | Apr 16, 2021 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 500 |
| CEO | Dr. Christopher C. Gibson Ph.D. |
Contact Details
Address: 41 South Rio Grande Street Salt Lake City, Utah United States | |
| Website | https://www.recursion.com |
Stock Details
| Ticker Symbol | RXRX |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001601830 |
| CUSIP Number | 75629V104 |
| ISIN Number | US75629V1044 |
| Employer ID | 46-4099738 |
| SIC Code | 2836 |
Key Executives
| Name | Position |
|---|---|
| Dr. Christopher C. Gibson Ph.D. | Co-Founder, Chief Executive Officer & Director |
| Ben R. Taylor | Chief Financial Officer & President of Recursion UK |
| Benjamin Mabey M.S. | Chief Technology Officer |
| Kristen Rushton M.B.A. | Chief Operating Officer |
| Nathan Hatfield | Chief Legal Officer & General Counsel |
| Dr. Blake C. Borgeson Ph.D. | Co-Founder & Director |
| Dr. David Hallett Ph.D. | Chief Scientific Officer |
| Dr. David J. Mauro M.D., Ph.D. | Chief Medical Officer |
| Jared Allenbach | Senior Director of Investor Relations |
| Kevin Leggat | Vice President of Finance & Accounting |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Dec 06, 2024 | 4 | Filing |
| Dec 03, 2024 | 8-K | Current Report |
| Dec 02, 2024 | 3 | Filing |
| Nov 27, 2024 | 8-K/A | [Amend] Current Report |
| Nov 26, 2024 | 8-K/A | [Amend] Current Report |
| Nov 22, 2024 | 4 | Filing |
| Nov 22, 2024 | 3 | Filing |
| Nov 20, 2024 | 8-K | Current Report |
| Nov 20, 2024 | S-8 | Filing |
| Nov 19, 2024 | 4 | Filing |